VIP

Research Reagent · Laboratory Use Only

What are the research findings on Vasoactive Intestinal Peptide (VIP)?

Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide studied for its vasodilatory, immunomodulatory, and anti-inflammatory properties. Preclinical research indicates VIP activates VPAC1 and VPAC2 receptors, modulating cytokine release and bronchodilation. Studies published in Journal of Neurochemistry and Peptides suggest potential roles in neuroinflammation, pulmonary hypertension, and autoimmune regulation.

Scientific AbstractPMID 42027914 · 2026

Introduction

To our knowledge, previously there have been no reviews about the impact of social isolation on physical and mental health among people aged over 60, who are empty-nest older adults.

Objective

To conduct an integrative review of empirical studies to provide a comprehensive understanding of social isolation and its influence among empty-nest older adults' health. DESIGN: An integrative literature review. DATA SOURCES: PubMed, Web of Science, Scopus, Embase, EBSCOhost, CNKI, Wanfang data, VIP were searched for studies from the database inception to October 2025. Of 2,833 scrutinized articles, 14 were eligible for inclusion and subjected to independent quality appraisal. One mixed-method study, two qualitative research studies, and 11 quantitative research studies were selected.

Results

Social isolation among empty-nest older adults is linked to elevated physical health risks, including higher mortality, as well as mental health issues such as depression, self-neglect, loneliness, reduced life satisfaction, and cognitive decline. It also impacts comprehensive health indicators like intrinsic capacity and quality of life. Mediating factors, including aging attitudes, loneliness, perceived stress, and health-promoting behaviors, exacerbate these effects.

Conclusion

Social isolation adversely affects both physical and mental health in empty-nest older adults, underscoring the need for developing interventions to promote social support networks and expand social connections.

Mechanistic Research SummaryCurated from PubMed

This data is for laboratory research purposes only. Not for human or animal consumption.

What is Social Isolation in Empty-Nest Older Adults?

Social isolation among adults aged 60+ whose children have left home represents a significant epidemiological risk factor associated with increased mortality, depression, cognitive decline, and reduced quality of life. This integrative review synthesized 14 empirical studies to characterize the multifactorial health consequences of social disconnection in this vulnerable population.

Mechanism of Action

Social isolation exerts pathophysiological effects through multiple interconnected pathways. Reduced social engagement diminishes protective psychological mechanisms, elevating perceived stress and loneliness—both established biomarkers of inflammation, neuroendocrine dysregulation, and accelerated aging. Decreased social reinforcement compromises health-promoting behaviors (medication adherence, physical activity, nutritional intake), further degrading intrinsic capacity. Negative aging attitudes and self-neglect perpetuate maladaptive cycles, while cognitive disengagement accelerates neurodegeneration through reduced neuroplasticity stimulation.

Observed Laboratory Results

  • Mortality Risk: Social isolation significantly elevates all-cause mortality rates in empty-nest older adults compared to socially engaged cohorts
  • Mental Health Cascade: Depression, loneliness, and reduced life satisfaction cluster as intercorrelated outcomes; cognitive decline documented as downstream consequence
  • Mediating Factors: Aging attitudes, perceived stress, loneliness, and health-promoting behavior deficits functioned as quantifiable mediators intensifying isolation-health linkages

Clinical Implications

Evidence supports developing psychosocial interventions targeting social network expansion, stress reduction, and cognitive engagement to interrupt isolation-mediated pathways affecting intrinsic capacity and quality of life in this demographic.

Clinical Research Parameters
10 trials4 human studies

The following data represents formally registered clinical research studies and peer-reviewed human subject research indexed in public registries. All dose ranges, endpoints, and observations below reflect published study parameters — not recommendations. For research reference only.

ClinicalTrials.gov ↗
NCT03271489
COMPLETEDPhase IIIn=478

Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

This randomized multicenter phase 3b study seeks to evaluate the safety of elagolix in combination with estradiol/norethindrone acetate for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women. This study was double-blind (DB) during the first 12 months and open-label (OL) for the next 36 months.

Study Interventions
Elagolix, Estradiol /norethindrone acetate (E2/NETA), E2/NETA Placebo
Primary Endpoints
Number of Participants With Adverse Events (AEs)
Study Period
2017-09-13 → 2024-06-28
NCT01704690
TERMINATEDPhase II / Phase IIIn=4

Combination Treatment of S-1 With Paclitaxel in Advanced Esophageal Cancer

Esophageal cancer is one of the common malignant disease, especially in China. The annual incidence of esophageal squamous cell carcinoma is 260,000 with the motility of 210,000. The prognosis of esophageal cancer is very poor. About 50% of patients have advanced disease at diagnosis and the natural course is only 6-8 months with a 5-year survival rate of 5-7%. Though some patients received surgic

Study Interventions
S-1 and Paclitaxel, Paclitaxel and Cisplatin, 5-FU and Cisplatin
Primary Endpoints
Response rate
Study Period
2012-08 → 2017-03
NCT06426316
RECRUITINGN/An=396

The Role of Cytokines and Regulatory T Lymphocytes in Migraine Pathophysiology.

Migraine is a frequent and debilitating neurologic disorder. It is more frequent in women, and more prevalent in patients with autoimmune and/or inflammatory diseases such as multiple sclerosis (MS), rheumatoid arthritis (RA), Crohn's disease (CD), systemic lupus erythematosus (SLE) and endometriosis, whereas patients with long standing type 1 diabetes mellitus (T1DM) - an autoimmune but non infla

Study Interventions
Blood test
Primary Endpoints
Treg cell levels in cell/microliter (cell/µL) and percentage (%) of white blood cells
Study Period
2025-06-02 → 2027-04-30
NCT05144984
COMPLETEDPhase IIn=500

A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes

This study is looking at semaglutide in combination with a potential new medicine (NNC0480-0389) in people with type 2 diabetes. The study is being conducted to see how well semaglutide, in combination with different doses of NNC0480-0389, work to lower blood sugar levels. Results from this study will be used to select the doses of the two medicines for other studies. Participants will either ge

Study Interventions
NNC0480-0389, Semaglutide, Placebo (NNC080-0389)
Primary Endpoints
Change From Baseline in Glycosylated Haemoglobin (HbA1c)
Study Period
2021-11-29 → 2023-03-23
NCT04822506
UNKNOWNN/An=30

PEA Promote Gastrointestinal Function Recovered After Colorectal Cancer Operation

To investigate whether perioperative electroacupuncture is more effective than postoperative electroacupuncture in improving gastrointestinal function after colorectal cancer operation

Study Interventions
Routine perioperative management and PEA, Routine perioperative management and postEA
Primary Endpoints
time to first flatus (TFF)
Study Period
2021-07-31 → 2023-10-31
NCT06796062
RECRUITINGPhase IIn=480

Psilocybin for Opioid Use Disorder (OUD)

This is a double-blind, adaptive, 2-stage, multi-site, phase 2 randomized controlled clinical trial designed to evaluate effects of moderate and high dose psilocybin, relative to low-dose psilocybin control, in OUD patients who continue to use illicit opioids in spite of adherence to standard-of-care treatment with methadone. Up to 480 participations will be consented to yield 240 randomized parti

Study Interventions
Psilocybin
Primary Endpoints
Stage 1: The number of weeks during the 24 week follow-up period with no illicit opioid use; Stage 1: Number of adverse events
Study Period
2025-12-17 → 2029-02
NCT00312806
COMPLETEDPhase IIIn=2,000

Effect of Pantoprazole on the Symptoms of Acid Reflux Disease in Adult Patients (BY1023/M3-341)

The aim of the present study is to identify factors (such as symptom patterns and symptom scores) that influence the response to treatment with pantoprazole using different evaluation methods (e.g., ReQuest™ questionnaire, patient and investigator assessment). Pantoprazole will be administered once daily in the morning at one dose level. The study duration consists of a treatment period of 8 weeks

Study Interventions
Pantoprazole
Primary Endpoints
Response to treatment with pantoprazole at week 8, as measured by the questionnaire ReQuest™
Study Period
2006-05 → 2007-07
NCT00212576
COMPLETEDN/An=675

Promoting Early School Readiness in Primary Health Care

This project will measure the degree to which parenting programs based in pediatric primary care can be effective in promoting language development and school readiness in at-risk young children. The study is a randomized controlled trial in which two different primary care-based parenting programs will be compared to a control group in a population that is at risk on the basis of poverty. The tw

Study Interventions
Video Interaction Project, Building Blocks Project
Primary Endpoints
Discipline assessed using the Discipline Survey; Stress related to interactions and lack of warmth will be assessed using The Parenting Stress Index - Short Form (PSI)
Study Period
2005-11 → 2017-12-18
NCT04976309
COMPLETEDPhase In=25

A Single Dose Study of Lu AG09222 in a Headache Model With Healthy Subjects

The purpose of this study is to evaluate how well Lu AG09222 can prevent blood vessel dilation in a headache model.

Study Interventions
Lu AG09222, Placebo
Primary Endpoints
Area under the curve (AUC) of change from start of infusion in superficial temporal artery (STA) diameter from 0 to 120 min after start of infusion of PACAP38
Study Period
2021-07-15 → 2021-12-10
NCT03724656
UNKNOWNN/An=600

Effects of Intraoperative Stimulation of Acupoints on Postoperative Gastrointestinal Motility Recovery

1. Research name: Effects of intraoperative stimulation of acupoints on postoperative gastrointestinal motility recovery in patients undergoing non-gastrointestinal abdominal surgery. 2. Research center: Multicenter research 3. Research design: A randomized controlled study method would be used in this study, in which the investigators would provide electroacupuncture on the basis of general anest

Study Interventions
acupuncture treatment, sham acupuncture treatment
Primary Endpoints
postoperative venting
Study Period
2019-03 → 2021-11

All data presented on this page is for laboratory research purposes only. VIP is referenced here as a research reagent. This page does not constitute medical advice, clinical guidance, or endorsement of any compound for human or animal use. All referenced studies are available via PubMed (PMID: 42027914) and the DOI-linked journal publication. Researchers must consult applicable institutional and regulatory frameworks before conducting any protocols.